骨肉瘤中Galectin-9和CD8的表达与临床病理特征及预后相关性分析

doi:10.11904/j.issn.1002-3070.2023.04.007

实用肿瘤学杂志 ›› 2023, Vol. 37 ›› Issue (4): 337-343.doi: 10.11904/j.issn.1002-3070.2023.04.007

骨肉瘤中Galectin-9和CD8的表达与临床病理特征及预后相关性分析

颜春辉, 喻玲, 何文源, 崔文志, 王卓才, 闫广宁

中国人民解放军南部战区总医院病理科(广州 510010)

收稿日期:2022-08-16 修回日期:2023-02-01 出版日期:2023-08-28 发布日期:2023-12-12
通讯作者: 闫广宁,E-mail:cawafrog@hotmail.com
作者简介:颜春辉,女,(1991-),硕士,主治医师,从事肿瘤免疫方面的研究。
基金资助:
国家自然科学青年基金(编号:81802962)

Expression of Galectin-9 and CD8 in osteosarcoma and their correlation with clinical pathological characteristics and prognosis

YAN Chunhui, YU Ling, HE Wenyuan, CUI Wenzhi, WANG Zhuocai, YAN Guangning

Department of Pathology, General Hospital of Southern Theatre Command, Guangzhou 510010, China

Received:2022-08-16 Revised:2023-02-01 Online:2023-08-28 Published:2023-12-12

摘要/Abstract

摘要： 目的检测骨肉瘤组织中Galectin-9(Gal-9)和CD8的表达,分析其表达水平与骨肉瘤临床病理特征的关系,探讨对预后的影响。方法本研究纳入2006—2016年期间初诊初治行手术切除并术后病理证实为骨肉瘤患者58例,并收集其临床及病理资料。检测Gal-9及CD8的表达并分析对骨肉瘤患者的无进展生存期(DFS)和总生存期(OS)的影响。结果免疫组化结果显示Gal-9低表达47例(81.0%),高表达11例(19.0%);CD8低表达28例(48.3%),高表达30例(51.7%)。Gal-9高表达组相比低表达组,肿瘤直径显著增大(P＜0.05);CD8低表达相比高表达组,DFS显著缩短(P＜0.05)。Gal-9低表达且CD8高表达组(n=24)女性比例更高,肿瘤直径较小,DFS和OS均更长(P＜0.05)。多因素Cox回归分析显示,Gal-9低表达且CD8高表达是影响骨肉瘤患者DFS和OS的独立因素(P＜0.05)。结论骨肉瘤患者Gal-9低表达且CD8高表达提示预后较好,可以为骨肉瘤患者预后分层和免疫治疗靶点选择提供依据。

关键词: 骨肉瘤, Galectin-9, CD8, 预后

Abstract: Objective The objective of this study was to detect the expressions of Galectin-9(Gal-9)and CD8 in osteosarcoma tissues, analyze the relationship between their expression and the clinical pathological features of osteosarcoma, and explore the impact on prognosis. Methods This study included 58 patients with initial diagnosis, surgical resection, and postoperative pathological confirmation of osteosarcoma from 2006 to 2016, and collected their clinical and pathological data. The expression of Gal-9 and CD8 was detected and the disease-free survival(DFS)and overall survival(OS)of osteosarcoma patients were statistically analyzed. Results The immunohistochemical results revealed that Gal-9 was low expressed in 47 cases(81.0%)and highly expressed in 11 cases(19.0%);CD8 was low expressed in 28 cases(48.3%)and highly expressed in 30 cases(51.7%). The high expression group of Gal-9 showed a significantly increase in tumor diameter compared to the low expression group(P＜0.05). Compared with the high expression group, the low expression group of CD8 significantly shortened DFS(P＜0.05). The group with low expression of Gal-9 and high expression of CD8(n=24)had a significantly higher proportion of women, shorter tumor diameter, and longer DFS and OS(P＜0.05). Multivariate Cox analysis showed that low expression of Gal-9 and high expression of CD8 were independent prognostic factors affecting DFS and OS in patients with osteosarcoma(P＜0.05). Conclusion Low expression of Gal-9 and high expression of CD8 in osteosarcoma patients indicate a better prognosis, which can provide a basis for prognostic stratification and selection of immunotherapy targets in osteosarcoma patients.

Key words: Osteosarcoma, Galectin-9, CD8, Prognosis

中图分类号:

R738

颜春辉, 喻玲, 何文源, 崔文志, 王卓才, 闫广宁. 骨肉瘤中Galectin-9和CD8的表达与临床病理特征及预后相关性分析[J]. 实用肿瘤学杂志, 2023, 37(4): 337-343.

YAN Chunhui, YU Ling, HE Wenyuan, CUI Wenzhi, WANG Zhuocai, YAN Guangning. Expression of Galectin-9 and CD8 in osteosarcoma and their correlation with clinical pathological characteristics and prognosis[J]. Journal of Practical Oncology, 2023, 37(4): 337-343.

0
/ / 推荐

导出引用管理器 EndNote|Reference Manager|ProCite|BibTeX|RefWorks

链接本文: http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/10.11904/j.issn.1002-3070.2023.04.007

http://journal09.magtechjournal.com/Jwk3_syzlxzz/CN/Y2023/V37/I4/337

参考文献

1 Liu Y,Huang N,Liao S,et al.Current research progress in targeted anti‐angiogenesis therapy for osteosarcoma[J].Cell proliferation,2021,54(9):e13102.
2 Zhang Y,Zhao H,Xu W,et al.High expression of PQBP1 and low expression of PCK2 are associated with metastasis and recurrence of osteosarcoma and unfavorable survival outcomes of the patients[J].J Cancer,2019,10(9):2091.
3 Shi Y,Tomczak K,Li J,et al.Next-generation immunotherapies to improve anticancer immunity[J].Front Pharmacol,2021,11:566401.
4 He QF,Xu Y,Li J,et al.CD8+ T-cell exhaustion in cancer:mechanisms and new area for cancer immunotherapy[J].Brief Funct Genomics,2019,18(2):99-106.
5 Heymann MF,Lézot F,Heymann D.The contribution of immune infiltrates and the local microenvironment in the pathogenesis of osteosarcoma[J].Cell Immunol,2019,343:103711.
6 Yang R,Sun L,Li CF,et al.Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy[J].Nat Commun,2021,12(1):832.
7 Thanindratarn P,Wei R,Dean DC,et al.T‐LAK cell‐originated protein kinase(TOPK):an emerging prognostic biomarker and therapeutic target in osteosarcoma[J].Mol Oncol,2021,15(12):3721-3737.
8 Yao Z,Tan Z,Yang J,et al.Prognostic nomogram for predicting 5-year overall survival in Chinese patients with high-grade osteosarcoma[J].Sci Rep,2021,11(1):17728.
9 胡越皓,鲍其远,沈宇辉,等.程序性死亡受体1及其配体抑制剂治疗骨肉瘤的研究进展[J].国际骨科学杂志,2019,40(5):263-267.
10 Zheng B,Ren T,Huang Y,et al.PD-1 axis expression in musculoskeletal tumors and antitumor effect of nivolumab in osteosarcoma model of humanized mouse[J].J Hematol Oncol,2018,11(1):16.
11 Fritzsching B,Fellenberg J,Moskovszky L,et al.CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors:a multicenter validated retrospective study[J].Oncoimmunology,2015,4(3):e990800.
12 费腾.TIM-3分子与肿瘤免疫抑制[J].中国肿瘤生物治疗杂志,2020,27(2):199-203.
13 He Y,Jia K,Dziadziuszko R,et al.Galectin-9 in non-small cell lung cancer[J].Lung Cancer,2019,136:80-85.
14 谢仁古丽·阿力木,曾雪娇,庞楠楠,等.TIM-3/galectin-9参与慢性淋巴细胞白血病患者T细胞的负性调控[J].细胞与分子免疫学杂志,2020,36(11):1021-1025.
15 Yang R,Sun L,Li CF,et al.Development and characterization of anti-galectin-9 antibodies that protect T cells from galectin-9-induced cell death[J].J Biol Chem,2022,298(4):101821.
16 王扬扬,郑骁,朱纯超,等.胃食管结合部腺癌组织中免疫检查点Tim-3/Gal-9表达及T细胞浸润分析[J].上海交通大学学报,2020,40(6):847-855.
17 Liang T,Wang X,Wang F,et al.Galectin-9:A predictive biomarker negatively regulating immune response in glioma patients[J].World Neurosurg,2019,132:e455-e462.
18 Zhou X,Sun L,Jing D,et al.Galectin-9 expression predicts favorable clinical outcome in solid tumors:a systematic review and meta-analysis[J].Front Physiol,2018,9:452.
19 Li X,Chen Y,Liu X,et al.TIM-3/Gal9 interactions between T cells and monocytes result in an immunosuppressive feedback loop that inhibits Th1 responses in osteosarcoma patients[J].Int Immunopharmacol,2017,44:153-159.
20 王明明,陈晓品.抗PD-1/PD-L1和CTLA-4免疫治疗在头颈鳞癌中的研究进展[J].实用肿瘤学杂志,2021,35(2):179-183.

[1]	苗玲, 赵之寒, 王敏. 非小细胞肺癌患者肿瘤组织PA28γ、miR-7-5p的表达水平及临床意义[J]. 实用肿瘤学杂志, 2023, 37(4): 344-350.
[2]	向迪, 寇丽娜, 杜春玲, 欧小文综述, 陈铁军审校. 全身免疫炎症指数与结直肠癌预后的研究进展[J]. 实用肿瘤学杂志, 2023, 37(4): 377-382.
[3]	崔永康, 于承平, 许浩志, 马新宇, 麻勇, 李林强. 营养风险指数在可切除肝细胞癌患者术后并发症及预后预测中的作用[J]. 实用肿瘤学杂志, 2023, 37(3): 243-251.
[4]	陈琪, 何明旭, 贾科良, 苗健龙, 韩丽萍. TP53-EGFR共突变对非小细胞肺癌预后及治疗的研究进展[J]. 实用肿瘤学杂志, 2023, 37(3): 262-266.
[5]	张一丹, 钟锐, 孙振轩, 王腾, 刘金涛. SYT13在癌症中的研究进展[J]. 实用肿瘤学杂志, 2023, 37(2): 181-184.
[6]	夏前林, 仇荣, 陆悦, 张琼, 杜玉珍. 肺腺癌m6A甲基化调控因子相关预后风险模型的构建及临床意义[J]. 实用肿瘤学杂志, 2023, 37(1): 39-45.
[7]	教冲, 史雨鑫, 徐浩译, 马斌林, 董朝. 二甲双胍对不同亚型乳腺癌伴2型糖尿病患者预后影响的研究[J]. 实用肿瘤学杂志, 2022, 36(6): 531-537.
[8]	徐子涵, 于国华, 聂玉辉, 孙蒙蒙, 丰慧, 刘淑真. 外周血标志物对晚期非小细胞肺癌免疫相关不良反应的预测作用及与生存结局的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(6): 544-550.
[9]	张浩, 杨新官, 何涌. 肌少症与晚期非小细胞肺癌临床病理特征及预后的相关性分析[J]. 实用肿瘤学杂志, 2022, 36(3): 214-219.
[10]	王洪英, 李岩, 韩鑫浩, 魏孝礼, 贾慧珣, 袁文娟, 张秋菊. 基于免疫相关lncRNAs的胃癌早期诊断和预后风险模型的构建和验证[J]. 实用肿瘤学杂志, 2022, 36(2): 119-126.
[11]	尹翼, 欧朝阳, 何爱琴. GAB2在卵巢癌组织中的表达及其与预后的相关性[J]. 实用肿瘤学杂志, 2022, 36(2): 150-155.
[12]	李伟华, 张广凤, 马骊骊, 何品, 王雯, 李顶夫. 基于TCGA数据库代谢相关基因构建乳腺癌预后模型[J]. 实用肿瘤学杂志, 2022, 36(1): 37-43.
[13]	王榆平, 思美丽, 孙小霞, 郭玉琳. HPIP在子宫内膜癌中高表达及其在生存预后分析中的意义[J]. 实用肿瘤学杂志, 2022, 36(1): 44-48.
[14]	曹世玉, 姜永冬. 基因表达与多基因检测以及生物标志物对Luminal A型乳腺癌预后的影响[J]. 实用肿瘤学杂志, 2022, 36(1): 89-93.
[15]	王丽娜, 王乐, 靳红, 李奇, 成海燕. UBQLN1在宫颈癌中的表达及其对预后的影响[J]. 实用肿瘤学杂志, 2021, 35(6): 506-510.

骨肉瘤中Galectin-9和CD8的表达与临床病理特征及预后相关性分析

Expression of Galectin-9 and CD8 in osteosarcoma and their correlation with clinical pathological characteristics and prognosis

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价